In this opinion piece, Lady Deborah Chambers KC examines the landmark judgment in Bell v Tavistock and the difficult balance between judicial review and political decision-making.
At age 15, Ms Bell was referred to the Tavistock gender clinic and prescribed puberty blockers. At 17 she was given testosterone, and despite experiencing what she says were serious doubts about her transition, Ms Bell underwent a bilateral mastectomy at age 20.
She later described a traumatic childhood marked by gender nonconformity, depression, anxiety, social disconnection and body hatred. Online research led her to believe she had found the answer to her problems, that she was trapped in the wrong body and was really a male. Later when she attempted to detransition, she discovered that many of the physical effects were irreversible.
In her early twenties, Ms Bell sought judicial review against the Tavistock Clinic, arguing it should never have facilitated such a rash decision by a teenager. The English High Court in Bell v Tavistock found there was only limited evidence of the efficacy, purpose and long-term effects of puberty blockers for gender dysphoria. It was right to call the treatment experimental. The court criticised the clinic’s failure to analyse its own data, particularly the dramatic rise in referrals (especially among females), the near-universal progression from blockers to cross-sex hormones, and the high rates of autism and comorbid mental health conditions among patients.
The judges noted that practically all children placed on puberty blockers proceeded to cross-sex hormones, with very few desisting. They described the interventions as highly unusual because they involved radical physical changes for a condition with no direct physical manifestations. The consequences were “highly complex and potentially life-changing in the most fundamental way imaginable, quite possibly uniquely.” The court was unequivocal: giving children lifelong, life-altering treatment with very limited knowledge of its benefits raised “significant grounds for concern.” It held that it was highly unlikely a child of 13 or younger could consent, and doubtful even for 14- or 15-year-olds.
The judgment prompted the NHS to immediately suspend referrals for under-16s. Although the clinic succeeded on appeal, the High Court’s findings fed directly into the independent Cass Review. Dr Hilary Cass, a former president of the Royal College of Paediatrics and Child Health, concluded that the NHS had let down vulnerable children by yielding to activist pressure. The review found no reliable evidence that puberty blockers “buy time to think,” improve body image, or deliver long-term benefits.
The Bell judgment showed the constitutional dance between courts and Parliament balance at its best: it made the previously unsayable suddenly sayable in mainstream public discourse. Three senior judges exposed the evidence gaps, consent problems and experimental nature of the treatment. Within days, the NHS acted. This opened the door for the Cass Review and, ultimately, for Parliament itself. NHS whistleblowers had raised alarms for years, only to be dismissed as bigots intent on denying “trans kids” life-saving treatment”. Such was the pitch of the debate: query puberty blockers and you were cast as complicit in the death of trans kids.
Questioning the use of experimental drugs on vulnerable children – including those with autism or same-sex attraction – was treated as heresy. The readiness with which these drugs were prescribed is now recognised as one of the most troubling medical scandals of our time. It was sustained by the silencing of dissent and an unforgiving demand for conformity. When debate is curtailed, poor policies take root with alarming speed.
The trans issue highlights deeper failures: the marginalisation of ordinary citizens’ views in favour of well-organised interest groups, and the willingness of public bodies to prioritise feelings and activism over objective evidence. Hilary Cass’s findings were damning. The Gender Identity Development Service was dismantled after years of administering life-changing treatments with inadequate understanding of the drugs and poor record-keeping.
The NHS now acknowledges that little is known about the long-term side effects of puberty blockers on children with gender dysphoria, including impacts on bone density and brain development. The editor of the British Medical Journal has stated that studies in gender medicine “fall woefully short in terms of methodological rigor”. These are deeply troubling indictments.
Following the Cass Report, NHS England effectively ceased using puberty blockers. The Conservative government imposed an emergency ban for under-18s, which the incoming Labour health secretary confirmed would continue indefinitely.
This shift in the UK aligns with decisions in other countries. Sweden, Finland, Norway and Denmark have all sharply restricted puberty blockers for gender dysphoria in minors after their own systematic reviews, limiting their use to exceptional cases or tightly controlled research.
In New Zealand, on 19 November 2025, Health Minister Hon Simeon Brown announced regulations under the Medicines Act 1981 prohibiting new prescriptions of puberty blockers for gender dysphoria or incongruence in those under 18. The regulations took effect on 19 December 2025.
The decision was a classic exercise of executive power delegated by Parliament to the Minister. They followed a Ministry of Health evidence review that echoed the Cass findings and were enacted by a democratically elected coalition government with a clear policy mandate. Existing patients could continue with consent.
The decision has, predictably, triggered litigation. The Professional Association for Transgender Health Aotearoa (PATHA) launched a judicial review alleging inadequate consultation, the wrong decision-maker, improper political purpose, and breaches of the New Zealand Bill of Rights Act. In December 2025 the High Court granted interim relief preventing enforcement pending a full hearing. The Court of Appeal upheld that position in February 2026. The regulations remain on the statute book but are not being applied. The substantive hearing is scheduled for 6 and 7 May 2026.
Judicial review is a vital constitutional safeguard. It enables courts to ensure ministers and officials act within the powers Parliament has delegated, follow proper procedures, and avoid unreasonableness or improper purposes. Courts cannot strike down primary legislation; parliamentary sovereignty remains intact. However, the limits of judicial review of delegated legislation remain a hot potato. Judges are inclined to take power if they can, and lawyers, if it will help their clients, will argue fiercely that they should.
This case illustrates how the balance has shifted. Judicial review has become an increasingly easy vehicle for well-resourced pressure groups to challenge and stall democratically made political decisions on largely procedural grounds. Lawyers naturally focus on process, and courts are often receptive to such arguments. While due process matters, when unelected judges intervene on technicalities in highly contested policy areas, a decision taken by elected politicians, with access to policy units, scientific advisors, cabinet processes and a public mandate, can be placed in indefinite limbo.
The risk is that persistent pressure groups may effectively capture the judicial review process. A judge, properly attentive to the complainant’s legal arguments, may not have evidence produced of a broader public interest or the weight of international evidence. The temptation to align with an ideological cause that has captured many institutions can prove stronger than the duty to protect vulnerable children.
The fault does not lie with individual judges, who apply doctrines that have expanded over decades. The deeper problem is the creeping judicialisation of politics and the broad regulation-making powers Parliament has conferred without sufficient guardrails.
The solution is not to abolish judicial review but to restore its proper boundaries.
Courts should show greater deference on matters of regulatory policy, evidence evaluation and political priority, areas where elected governments possess both democratic mandate and institutional expertise. Parliament could assist by legislating clearer limits on interim relief in high-policy cases or by using more explicit statutory language to constrain implied procedural obligations.
Whatever the outcome of the May hearing, this case underscores why the boundary between judicial oversight and democratic decision-making must be carefully guarded. Democracy functions best when elected politicians are permitted to make the difficult calls they were elected to make, and when courts reserve intervention for genuine excesses of power rather than disagreements over evidence or ideology. Judicial review remains essential. But it must not become a veto power for the unelected.
This is an article from Lady Deborah Chambers KC’s fortnightly column published in The New Zealand Herald.
Comment